当前位置： SCI文献检索 > JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS期刊下所有文献 > Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

Abstract：

:Cell-level kinetic models for therapeutically relevant processes increasingly benefit the early stages of drug development. Later stages of the drug development processes, however, rely on pharmacokinetic compartment models while cell-level dynamics are typically neglected. We here present a systematic approach to integrate cell-level kinetic models and pharmacokinetic compartment models. Incorporating target dynamics into pharmacokinetic models is especially useful for the development of therapeutic antibodies because their effect and pharmacokinetics are inherently interdependent. The approach is illustrated by analysing the F(ab)-mediated inhibitory effect of therapeutic antibodies targeting the epidermal growth factor receptor. We build a multi-level model for anti-EGFR antibodies by combining a systems biology model with in vitro determined parameters and a pharmacokinetic model based on in vivo pharmacokinetic data. Using this model, we investigated in silico the impact of biochemical properties of anti-EGFR antibodies on their F(ab)-mediated inhibitory effect. The multi-level model suggests that the F(ab)-mediated inhibitory effect saturates with increasing drug-receptor affinity, thereby limiting the impact of increasing antibody affinity on improving the effect. This indicates that observed differences in the therapeutic effects of high affinity antibodies in the market and in clinical development may result mainly from Fc-mediated indirect mechanisms such as antibody-dependent cell cytotoxicity.

journal_name

J Pharmacokinet Pharmacodyn

journal_title

Journal of pharmacokinetics and pharmacodynamics

authors

Krippendorff BF,Oyarzún DA,Huisinga W

doi

10.1007/s10928-012-9243-7

subject

Has Abstract

pub_date

2012-04-01 00:00:00

pages

125-39

issue

2

eissn

1567-567X

issn

1573-8744

journal_volume

39

pub_type

杂志文章

相关文献

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS文献大全
  • Introduction to the analysis of PET data in oncology.

    abstract：:Several reviews on specific topics related to positron emission tomography (PET) ranging in complexity from introductory to highly technical have already been published. This introduction to the analysis of PET data was written as a simple guide of the different phases of analysis of a given PET dataset, from acquisit...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章,评审

    doi：10.1007/s10928-013-9307-3

    authors： Tomasi G,Aboagye EO

    更新日期：2013-08-01 00:00:00

  • The effect of using a robust optimality criterion in model based adaptive optimization.

    abstract：:Optimizing designs using robust (global) optimality criteria has been shown to be a more flexible approach compared to using local optimality criteria. Additionally, model based adaptive optimal design (MBAOD) may be less sensitive to misspecification in the prior information available at the design stage. In this wor...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-017-9521-5

    authors： Strömberg EA,Hooker AC

    更新日期：2017-08-01 00:00:00

  • A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

    abstract：:Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) scores. Throu...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-018-9581-1

    authors： Hu C,Yao Z,Chen Y,Randazzo B,Zhang L,Xu Z,Sharma A,Zhou H

    更新日期：2018-08-01 00:00:00

  • Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients.

    abstract：:Intravenous acetaminophen is a commonly used analgesic following surgery. The aims of this study were to determine the population pharmacokinetic profile of intravenous acetaminophen and its metabolites in adult surgical patients and to identify patient characteristics associated with acetaminophen metabolism in the p...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-014-9358-0

    authors： Owens KH,Murphy PG,Medlicott NJ,Kennedy J,Zacharias M,Curran N,Sreebhavan S,Thompson-Fawcett M,Reith DM

    更新日期：2014-06-01 00:00:00

  • A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.

    abstract：:HbA1c is the most commonly used biomarker for the adequacy of glycemic management in diabetic patients and a surrogate endpoint for anti-diabetic drug approval. In spite of an empirical description for the relationship between average glucose (AG) and HbA1c concentrations, obtained from the A1c-derived average glucose...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-012-9289-6

    authors： Lledó-García R,Mazer NA,Karlsson MO

    更新日期：2013-04-01 00:00:00

  • A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.

    abstract：:Although selective 5-HT reuptake inhibitors (SSRIs) block monoamine uptake within hours of administration to patients, their full clinical effect does not appear until 2-4 weeks after treatment onset. Pindolol, a betablocker with weak partial 5-HT1A receptor agonist activity has been shown to produce a more rapid onse...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-005-0006-6

    authors： Gruwez B,Dauphin A,Tod M

    更新日期：2005-12-01 00:00:00

  • Allometric scaling of pegylated liposomal anticancer drugs.

    abstract：:Pegylated liposomal formulations contain lipid conjugated to polyethylene glycol. The disposition of encapsulated drug is dictated by the composition of the liposome, thus altering the pharmacokinetic (PK) profile of the drug. Allometric scaling is based on a power-log relationship between body weight (W) and drug cle...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-011-9213-5

    authors： Caron WP,Clewell H,Dedrick R,Ramanathan RK,Davis WL,Yu N,Tonda M,Schellens JH,Beijnen JH,Zamboni WC

    更新日期：2011-10-01 00:00:00

  • Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

    abstract：:This study was designed to investigate the pharmacokinetics/pharmacodynamics (PK/PD) risk factors preceding the onset of type 2 diabetes using a population-based Bayesian nonlinear hierarchical model to describe the glucose-insulin kinetics. One hundred fifty-two healthy subjects with a family history of type 2 diabet...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-009-9130-z

    authors： Lin CW,Veng-Pedersen P

    更新日期：2009-10-01 00:00:00

  • Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

    abstract：:The utilisation of physiologically-based pharmacokinetic models for the analysis of population data is an approach with progressively increasing impact. However, as we move from empirical to complex mechanistic model structures, incorporation of stochastic variability in model parameters can be challenging due to the ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-015-9418-0

    authors： Tsamandouras N,Wendling T,Rostami-Hodjegan A,Galetin A,Aarons L

    更新日期：2015-08-01 00:00:00

  • A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.

    abstract：:HER2-positive breast cancer (BC) is a rapidly growing and aggressive BC subtype that predominantly affects younger women. Despite improvements in patient outcomes with anti-HER2 therapy, primary and/or acquired resistance remain a major clinical challenge. Here, we sought to use a quantitative systems pharmacological ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-020-09732-x

    authors： Franco YL,Ramakrishnan V,Vaidya TR,Mody H,Perez L,Ait-Oudhia S

    更新日期：2021-01-03 00:00:00

  • A reduction in between subject variability is not mandatory for selecting a new covariate.

    abstract：:Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed betwe...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-012-9256-2

    authors： Lagishetty CV,Vajjah P,Duffull SB

    更新日期：2012-08-01 00:00:00

  • Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

    abstract：:Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII). There is a strong non-linear feedback from AT1-bound AngII on renin secretion. Since AT...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-018-9612-y

    authors： Gebremichael Y,Lahu G,Vakilynejad M,Hallow KM

    更新日期：2019-02-01 00:00:00

  • Robust population pharmacokinetic experiment design.

    abstract：:The population approach to estimating mixed effects model parameters of interest in pharmacokinetic (PK) studies has been demonstrated to be an effective method in quantifying relevant population drug properties. The information available for each individual is usually sparse. As such, care should be taken to ensure t...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-005-2102-z

    authors： Dodds MG,Hooker AC,Vicini P

    更新日期：2005-02-01 00:00:00

  • Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach.

    abstract：:Neutropenia is a common side-effect of oncology drugs. We aimed to study the impact of exposure and dosing schedule on neutropenia to guide selection of dosing schedules that minimize neutropenia potential while maintaining the desired minimum concentration (Cmin) required for target engagement. Dose, frequency and PK...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-019-09667-y

    authors： Guo Y,Haddish-Berhane N,Xie H,Ouellet D

    更新日期：2020-02-01 00:00:00

  • Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

    abstract：:In this work a model for analyzing categorical data is presented; the differential odds model. Unlike the commonly used proportional odds model, this model does not assume that a covariate affects all categories equally on the log odds scale. The differential odds model was compared to the proportional odds model, by ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-008-9098-0

    authors： Kjellsson MC,Zingmark PH,Jonsson EN,Karlsson MO

    更新日期：2008-10-01 00:00:00

  • General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

    abstract：:Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characteriz...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1023/a:1014414520282

    authors： Mager DE,Jusko WJ

    更新日期：2001-12-01 00:00:00

  • Physiologically based synthetic models of hepatic disposition.

    abstract：:Current physiologically based pharmacokinetic (PBPK) models are inductive. We present an additional, different approach that is based on the synthetic rather than the inductive approach to modeling and simulation. It relies on object-oriented programming. A model of the referent system in its experimental context is s...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-006-9031-3

    authors： Hunt CA,Ropella GE,Yan L,Hung DY,Roberts MS

    更新日期：2006-12-01 00:00:00

  • Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole.

    abstract：:The aim of this study was to develop a population in vitro-in vivo pharmacokinetic model that simultaneously describe the absorption and accumulation kinetics of itraconazole (ICZ) and hydroxy-itraconazole (HICZ) in healthy subjects. The model integrated meta-models of gastrointestinal pH and gastrointestinal transit ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-017-9555-8

    authors： Abuhelwa AY,Mudge S,Upton RN,Foster DJR

    更新日期：2018-04-01 00:00:00

  • Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

    abstract：:The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-018-9586-9

    authors： Zang X,Kagan L

    更新日期：2018-08-01 00:00:00

  • Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.

    abstract：:Tocilizumab is a recombinant humanized antihuman interleukin-6 receptor monoclonal antibody, which inhibits binding of IL-6 to its soluble (sIL-6R) and membrane-expressed (mIL-6R) receptors. The work investigated whether the observed decline in peripheral neutrophil and platelet counts after tocilizumab administration...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10928-011-9227-z

    authors： Gibiansky L,Frey N

    更新日期：2012-02-01 00:00:00

  • A method of obtaining starting values of k(in) and k(out) for the indirect response models.

    abstract：:A method based on the multivariate technique known as principal component analysis is proposed to obtain starting values for the rate constants of indirect response models. The method is not iterative and only requires standard deviation calculations for two quantities, which are simple functions of the measured pharm...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1023/b:jopa.0000029487.21238.5c

    authors： Mukherjee D,Hutmacher MM

    更新日期：2004-02-01 00:00:00

  • Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.

    abstract：:The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological systems as described by mathematical (most often differential) equati...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-017-9546-9

    authors： Gibiansky L,Gibiansky E

    更新日期：2018-02-01 00:00:00

  • Reversible jump Markov chain Monte Carlo for deconvolution.

    abstract：:To solve the problem of estimating an unknown input function to a linear time invariant system we propose an adaptive non-parametric method based on reversible jump Markov chain Monte Carlo (RJMCMC). We use piecewise polynomial functions (splines) to represent the input function. The RJMCMC algorithm allows the explor...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-006-9045-x

    authors： Kang D,Verotta D

    更新日期：2007-06-01 00:00:00

  • Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

    abstract：:The physiologically based pharmacokinetic (PBPK) models allow for predictive assessment of variability in population of interest. One of the future application of PBPK modeling is in the field of precision dosing and personalized medicine. The aim of the study was to develop PBPK model for amitriptyline given orally, ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-018-9597-6

    authors： Tylutki Z,Mendyk A,Polak S

    更新日期：2018-10-01 00:00:00

  • A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

    abstract：:The pharmacokinetics of cyclosporin (CsA) are unusual because of several heterogeneous features which include the presence of more than one conformer, considerable accumulation in erythrocytes and lipoproteins, extensive plasma protein binding, distribution into deep tissues, biliary secretion and hepatic clearance in...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1023/a:1012295014352

    authors： Claret L,Iliadis A,Macheras P

    更新日期：2001-10-01 00:00:00

  • Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation.

    abstract：:Literature data are often reported as multiple (longitudinal) mean outcomes observed in several groups of patients within a study. Observations within a study are correlated because the patients come from a common population, and the mean observations over time within a treatment arm are correlated because they are ba...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-010-9152-6

    authors： Ahn JE,French JL

    更新日期：2010-04-01 00:00:00

  • A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients.

    abstract：:Long term therapy with antiretroviral agents in HIV-infected patients often result in failure to suppress the virus load. Imperfect adherence to prescribed antiviral drugs is an important factor explaining the resurgence of virus. A better understanding of the factors responsible for the virological failure is importa...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-006-9022-4

    authors： Labbé L,Verotta D

    更新日期：2006-08-01 00:00:00

  • Fractional kinetics in drug absorption and disposition processes.

    abstract：:We explore the use of fractional order differential equations for the analysis of datasets of various drug processes that present anomalous kinetics, i.e. kinetics that are non-exponential and are typically described by power-laws. A fractional differential equation corresponds to a differential equation with a deriva...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1007/s10928-009-9116-x

    authors： Dokoumetzidis A,Macheras P

    更新日期：2009-04-01 00:00:00

  • Evaluation of mixture modeling with count data using NONMEM.

    abstract：:Mixture modeling within the context of pharmacokinetic (PK)/pharmacodynamic (PD) mixed effects modeling is a useful tool to explore a population for the presence of two or more subpopulations, not explained by evaluated covariates. At present, statistical tests for the existence of mixed populations have not been deve...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章

    doi：10.1023/a:1025564409649

    authors： Frame B,Miller R,Lalonde RL

    更新日期：2003-06-01 00:00:00

  • Structural identifiability for mathematical pharmacology: models of myelosuppression.

    abstract：:Structural identifiability is an often overlooked, but essential, prerequisite to the experiment design stage. The application of structural identifiability analysis to models of myelosuppression is used to demonstrate the importance of its considerations. It is shown that, under certain assumptions, these models are ...

    journal_title：Journal of pharmacokinetics and pharmacodynamics

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10928-018-9569-x

    authors： Evans ND,Cheung SYA,Yates JWT

    更新日期：2018-02-01 00:00:00